

# REFERENCES

1. Roizen MF, Horrigan RW, Frazer BM: Anesthetic doses blocking adrenergic (stress) and cardio-vascular responses to incision MAC BAR. *ANESTHESIOLOGY* 54:390-398, 1981
2. Gillman MA, Kok L, Lichtigfeld FJ: Paradoxical effect of naloxone on nitrous oxide analgesia in man. *Eur J Pharmacol* 61:175-177, 1980
3. Yang JC, Clark WC, Ngai SH: Antagonism of nitrous oxide analgesia by naloxone in man. *ANESTHESIOLOGY* 52:414-417, 1980
4. Ahmed MS, Byrne WL: Opiate receptor binding studies of a reversible sulphhydryl reagent, Endogenous and Exogenous Opiate Agonists and Antagonists. Edited by Way EL. New York Pergamon, 1980, pp 51-54
5. Aghajanian GK: Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. *Nature* 276:186-187, 1978
6. Strahlendorf HK, Strahlendorf JC, Barnes CD: Endorphin-mediated inhibition of locus coeruleus neurones: *Brain Res* 191:284-288, 1980
7. Steinberg H: Effects of nitrous oxide on reactions to stress. *Bull Br Psychol Soc* 24:12, 1954
8. Russell RW, Steinberg H: Effects of nitrous oxide on reactions to "stress". *Q J Exp Psychol* 7:67-73, 1955
9. Lipton S: Pain relief, Recent Advances in Anaesthesia and Analgesia, no. 12. Edinburgh, London and New York, Churchill Livingstone, 1976, pp 234-260
10. Smolinskii KI: Use of nitrous oxide with oxygen in paroxysms of bronchial asthma. *Sov Med* 24:114, 1960
11. Gillman MA, Lichtigfeld FJ: Management of alcohol withdrawal symptoms. *Br Med J* 283:64, 1981

(Accepted for publication September 22, 1981.)

Anesthesiology  
56:235, 1982

## Pitfalls in Deriving Pharmacokinetic Variables. I

*To The Editor:*—The reports of Morgan *et al.*<sup>1,2</sup> and the editorial by Stanski<sup>3</sup> fail to emphasize several problems in deriving the rate of elimination of a drug from its plasma concentration *vs.* time curve.

One problem is that in analyzing the plasma concentration *vs.* time curve over several hours, it is not possible to distinguish between elimination or irreversible loss of the drug from the plasma, and distribution of the drug into tissues with especially long time constants. For instance, for thiopental assuming 75 per cent protein binding, 20 per cent of the body weight consisting of fat, a fat/blood partition coefficient of 11,<sup>4</sup> and 7 per cent of a 6 l/min cardiac output going to fat, the time constant for fat tissue would be approximately 22 hours. Ghoneim and van Hamme's<sup>5</sup> three-compartment model predicts that distribution will be complete in approximately 2.5 hours after the bolus administration. One may reasonably assume that after this time the distribution of thiopental into fat is not complete. In fact, it may not be complete at the end of their 12 hour data collection period; thus, the drug that goes to fat during this period appears to be irreversibly lost, that is, it appears to be excreted. A similar "overestimation" of the true elimination of other drugs used during anesthesia may be found if plasma levels of the parent drug can be determined for several days.

Another problem is that the model independent pharmacokinetic variables, clearance and apparent volume of distribution, are derived by integrating the plasma concentration *vs.* time curve from the time of drug administration to infinity. Obviously, the shorter the data collection period, the larger the possible error in the integration, and hence in these two variables.

Pharmacokinetic studies of drugs used during anesthesia in which data are collected for several hours are still quite useful to anesthesiologists because they do describe the amount of drug in the plasma, and presumably the rapidly equilibrating tissues during the course of the average anesthetic period. One must be aware that the shorter studies may overestimate the importance of drug elimination and underestimate the importance of drug distribution. Further studies are needed to attempt to correlate the variation in pharmacokinetic variables seen between individuals and variations in those factors which influence drug distribution such as cardiac output, degree of protein binding and regional blood flow.

GUY TANNER, M.D.

Assistant Professor Anesthesiology  
Yale University School of Medicine  
New Haven, Connecticut 06510

# REFERENCES

1. Morgan DJ, Blackman GL, Paull JD, et al: Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. *ANESTHESIOLOGY* 54:468-473, 1981
2. Morgan DJ, Blackman GL, Paull JD, et al: Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. *ANESTHESIOLOGY* 54:474-480, 1981
3. Stanski DR: Pharmacokinetic modelling of thiopental. *ANESTHESIOLOGY* 54:446-448, 1981
4. Saidman LJ: Uptake, distribution, and elimination of barbiturates, Anesthetic Uptake and Action. Edited by Eger EI II. Baltimore, Maryland, Williams and Wilkins, Co., 1974, pp 265
5. Ghoneim MM, Van Hamme MJ: Pharmacokinetics of thiopentone: Effects of enflurane and nitrous oxide anaesthesia and surgery. *Br J Anaesth* 50:1237-1241, 1978

(Accepted for publication September 22, 1981.)